• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于过渡金属的抗癌药物。

Transition metal based anticancer drugs.

机构信息

Nanoscale Organisation and Dynamics Group, School of Biomedical and Health Sciences, College of Health and Science, University of Western Sydney, Locked Bag 1797, Penrith South DC, 1797 NSW, Australia.

出版信息

Curr Top Med Chem. 2011;11(5):521-42. doi: 10.2174/156802611794785226.

DOI:10.2174/156802611794785226
PMID:21189131
Abstract

With an ageing baby-boomer population in the Western World, cancer is becoming a significant cause of death. The prevalence of cancer and all associated costs, both in human and financial terms, drives the search for new therapeutic drugs and treatments. Platinum anticancer agents, such as cisplatin have been highly successful but there are several disadvantages associated with their use. What is need are new compounds with different mechanisms of action and resistance profiles. What needs to be recognised is that there are many other metal in the periodic table with therapeutic potential. Here we have highlighted metal complexes with activity and have illustrate the different approaches to the design of anticancer complexes.

摘要

随着西方世界老龄化的婴儿潮一代人口的增加,癌症成为了一个重要的死亡原因。癌症的流行以及所有与之相关的人力和财力成本,促使人们不断寻找新的治疗药物和治疗方法。铂类抗癌药物,如顺铂,已经非常成功,但它们的使用也存在一些缺点。我们需要的是具有不同作用机制和耐药谱的新化合物。需要认识到,周期表中有许多其他金属具有治疗潜力。在这里,我们重点介绍了具有活性的金属配合物,并说明了设计抗癌配合物的不同方法。

相似文献

1
Transition metal based anticancer drugs.基于过渡金属的抗癌药物。
Curr Top Med Chem. 2011;11(5):521-42. doi: 10.2174/156802611794785226.
2
Metal-based drugs that break the rules.打破常规的金属基药物。
Dalton Trans. 2016 Feb 28;45(8):3201-9. doi: 10.1039/c5dt03919c. Epub 2016 Jan 28.
3
A survey of the mechanisms of action of anticancer transition metal complexes.抗癌过渡金属配合物作用机制的综述。
Future Med Chem. 2016 Dec;8(18):2263-2286. doi: 10.4155/fmc-2016-0153. Epub 2016 Nov 22.
4
Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.基于 2-丁酮缩硫代氨基脲的混合配体过渡金属配合物靶向组合库的计算机辅助药物设计和虚拟筛选。
Comput Biol Chem. 2018 Aug;75:178-195. doi: 10.1016/j.compbiolchem.2018.05.008. Epub 2018 May 8.
5
"Good Fashion is Evolution, Not Revolution" - Methods to Enhance Existing Anticancer Medicines, Primarily with the Use of Transition Metal.“好的时尚是进化,而非革命”——主要利用过渡金属增强现有抗癌药物的方法。
Anticancer Agents Med Chem. 2018;18(4):476-487. doi: 10.2174/1871520618666171129213132.
6
Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.顺铂及其他:癌症化疗中的作用分子机制与耐药性发展
Radiol Oncol. 2019 Mar 28;53(2):148-158. doi: 10.2478/raon-2019-0018.
7
Next-generation metal anticancer complexes: multitargeting via redox modulation.下一代金属抗癌配合物:通过氧化还原调节实现多靶点作用。
Inorg Chem. 2013 Nov 4;52(21):12276-91. doi: 10.1021/ic400835n. Epub 2013 Jul 23.
8
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.钌配合物的DNA结合模式及其与肿瘤细胞毒性的关系。
Drug Resist Updat. 2006 Jun;9(3):111-22. doi: 10.1016/j.drup.2006.05.002. Epub 2006 Jun 21.
9
Synthesis, characterization, biological and catalytic applications of transition metal complexes derived from Schiff base.席夫碱衍生的过渡金属配合物的合成、表征、生物学及催化应用
Bioorg Med Chem Lett. 2014 Aug 1;24(15):3559-64. doi: 10.1016/j.bmcl.2014.05.046. Epub 2014 May 23.
10
Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.药物基因组学研究揭示新型作用机制的有机铱类抗癌配合物。
Metallomics. 2018 Jan 24;10(1):93-107. doi: 10.1039/c7mt00242d.

引用本文的文献

1
Are the metal identity and stoichiometry of metal complexes important for colchicine site binding and inhibition of tubulin polymerization?金属配合物的金属种类和化学计量对于秋水仙素结合位点和微管蛋白聚合的抑制作用是否重要?
Dalton Trans. 2024 Jul 23;53(29):12349-12369. doi: 10.1039/d4dt01469c.
2
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.基于靶点的抗癌吲哚衍生物用于开发抗神经胶质瘤药物。
Molecules. 2023 Mar 13;28(6):2587. doi: 10.3390/molecules28062587.
3
Targeting of the intracellular redox balance by metal complexes towards anticancer therapy.
金属配合物针对细胞内氧化还原平衡用于抗癌治疗
Front Chem. 2022 Aug 11;10:967337. doi: 10.3389/fchem.2022.967337. eCollection 2022.
4
Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.基于非铂小金属的化学疗法的生物活性与发展
Pharmaceutics. 2022 Apr 28;14(5):954. doi: 10.3390/pharmaceutics14050954.
5
Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies.基于过渡金属-芳烃体系的有机金属化合物作为抗癌剂的研究范围:从经典范式到靶向多种策略。
RSC Adv. 2019 Jan 24;9(6):3239-3278. doi: 10.1039/c8ra07926a. eCollection 2019 Jan 22.
6
Left versus right: Exploring the effects of chiral threading intercalators using optical tweezers.左与右:利用光学镊子探索手性穿入插层剂的作用。
Biophys J. 2022 Oct 4;121(19):3745-3752. doi: 10.1016/j.bpj.2022.04.025. Epub 2022 Apr 25.
7
Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives.三羰基和二羰基抗癌和抗生素铼配合物:当前研究和未来展望。
Molecules. 2022 Jan 15;27(2):539. doi: 10.3390/molecules27020539.
8
Cytotoxic cobalt (III) Schiff base complexes: in vitro anti-proliferative, oxidative stress and gene expression studies in human breast and lung cancer cells.细胞毒性钴(III)席夫碱配合物:人乳腺癌和肺癌细胞的体外抗增殖、氧化应激及基因表达研究
Biometals. 2022 Feb;35(1):67-85. doi: 10.1007/s10534-021-00351-8. Epub 2021 Dec 22.
9
Synthetic Strategy Towards Heterodimetallic Half-Sandwich Complexes Based on a Symmetric Ditopic Ligand.基于对称双齿配体的异双核半夹心配合物的合成策略。
Front Chem. 2021 Dec 3;9:786367. doi: 10.3389/fchem.2021.786367. eCollection 2021.
10
Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment.钌配合物:结直肠癌治疗中铂类药物的替代物
Pharmaceutics. 2021 Aug 19;13(8):1295. doi: 10.3390/pharmaceutics13081295.